Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMP360 Psilocybin in Treatment-Resistant Depression
NCT03775200Phase 2Completed
- Sponsor
- COMPASS Pathways
- Start
- Mar 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of COMP360 in major depressive disorder (MDD), sponsored by COMPASS Pathways. Started Mar 2019; status: completed.
02
Drugs
COMP360
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03775200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775200.